BMS-986218 + Nivolumab + Docetaxel for Prostate Cancer

"This medical trial requires 204 voluntary participants that qualify for the inclusion criteria. Intending volunteers can take part from various sites, such as University of Texas MD Anderson Cancer Center in Columbia, Maryland and Willamette Valley Cancer Institute And Research Center in Tampa, Florida."

"Docetaxel is predominantly employed to address cancerous neoplasms, but can also be utilized for treating a multitude of other illnesses such as unresectable melanoma, squamous cell carcinoma and sarcoma."

"This trial, which entails a 4 year period of observation and monitoring, aims to measure the frequency of adverse events (AEs). Secondary objectives include measuring AEs leading to discontinuation as classified in Part 2, duration of response per Prostate cancer Working Group 3 (DOR-PCWG3) as stipulated in Part 2, and death rate according to Part 2."

"There is some evidence of the safety profile for Docetaxel, so it has been assigned a score of 2. In this Phase 2 clinical trial, efficacy data remains absent."

"Across the United States, 33 clinical trial sites are recruiting patients to participate in this research. Prominent locations include University of Texas MD Anderson Cancer Center (Columbia), Willamette Valley Cancer Institute and Research Centre (Tampa), and Texas Oncology (Marietta)."

"Currently, there are 1,016 clinical trials studying the effects of Docetaxel. Specifically, 201 live studies in Phase 3 have been documented with 61190 locations running experiments on this drug located predominantly in Fuzhou, Fujian."

"As per clinicaltrials.gov, this trial is recruiting participants as of now. The listing was initially posted on February 14th 2022 and changed most recently on August 1st 2022."